-
Je něco špatně v tomto záznamu ?
Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid
M. Stiborová, E. Frei, VM. Arlt, HH. Schmeiser,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Odkazy
PubMed
24152141
DOI
10.3109/00498254.2013.848310
Knihovny.cz E-zdroje
- MeSH
- adukty DNA metabolismus MeSH
- cytochrom P-450 CYP1A1 genetika metabolismus MeSH
- cytochrom P-450 CYP1A2 genetika metabolismus MeSH
- enzymy genetika metabolismus MeSH
- inhibitory enzymů farmakologie MeSH
- karcinogeny metabolismus farmakokinetika MeSH
- kyseliny aristolochové metabolismus farmakokinetika toxicita MeSH
- lidé MeSH
- metabolická inaktivace * MeSH
- myši knockoutované * MeSH
- myši MeSH
- NAD(P)H dehydrogenasa (chinon) antagonisté a inhibitory MeSH
- NADPH-cytochrom c-reduktasa genetika metabolismus MeSH
- nemoci ledvin chemicky indukované MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
UNLABELLED: 1. Aristolochic acid I (AAI) is the predominant component in plant extract of Aristolochia genus that is involved in development of aristolochic acid nephropathy, Balkan endemic nephropathy and urothelial cancer. The diseases do not develop in all individuals exposed to AAI and patients exhibit different clinical outcomes. Differences in the activities of enzymes catalyzing the metabolism of AAI might be one of the reasons for this individual susceptibility. 2. Understanding which human enzymes are involved in reductive activation of AAI generating AAI-DNA adducts, and/or its detoxication to the O-demethylated metabolite, aristolochic acid Ia (AAIa), is necessary in the assessment of the susceptibility to this compound. 3. This review summarizes the results of the latest studies utilizing genetically engineered mouse models to identify which human and rodent enzymes catalyze the reductive activation of AAI to AAI-DNA adducts and its oxidative detoxication to AAIa in vivo. 4. The use of hepatic cytochrome P450 (Cyp) reductase null (HRN) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes, Cyp1a1((-/-)), Cyp1a2((-/-)) single-knockout, Cyp1a1/1a2((-/-)) double-knockout and CYP1A-humanized mice revealed that mouse and human CYP1A1 and 1A2, besides mouse NAD(P)H: quinone oxidoreductase, were involved in the activation of AAI but CYP1A1 and 1A2 also oxidatively detoxified AAI.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008536
- 003
- CZ-PrNML
- 005
- 20171215201513.0
- 007
- ta
- 008
- 150306s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/00498254.2013.848310 $2 doi
- 035 __
- $a (PubMed)24152141
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University , Prague , Czech Republic .
- 245 10
- $a Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid / $c M. Stiborová, E. Frei, VM. Arlt, HH. Schmeiser,
- 520 9_
- $a UNLABELLED: 1. Aristolochic acid I (AAI) is the predominant component in plant extract of Aristolochia genus that is involved in development of aristolochic acid nephropathy, Balkan endemic nephropathy and urothelial cancer. The diseases do not develop in all individuals exposed to AAI and patients exhibit different clinical outcomes. Differences in the activities of enzymes catalyzing the metabolism of AAI might be one of the reasons for this individual susceptibility. 2. Understanding which human enzymes are involved in reductive activation of AAI generating AAI-DNA adducts, and/or its detoxication to the O-demethylated metabolite, aristolochic acid Ia (AAIa), is necessary in the assessment of the susceptibility to this compound. 3. This review summarizes the results of the latest studies utilizing genetically engineered mouse models to identify which human and rodent enzymes catalyze the reductive activation of AAI to AAI-DNA adducts and its oxidative detoxication to AAIa in vivo. 4. The use of hepatic cytochrome P450 (Cyp) reductase null (HRN) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes, Cyp1a1((-/-)), Cyp1a2((-/-)) single-knockout, Cyp1a1/1a2((-/-)) double-knockout and CYP1A-humanized mice revealed that mouse and human CYP1A1 and 1A2, besides mouse NAD(P)H: quinone oxidoreductase, were involved in the activation of AAI but CYP1A1 and 1A2 also oxidatively detoxified AAI.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kyseliny aristolochové $x metabolismus $x farmakokinetika $x toxicita $7 D034341
- 650 _2
- $a karcinogeny $x metabolismus $x farmakokinetika $7 D002273
- 650 _2
- $a cytochrom P-450 CYP1A1 $x genetika $x metabolismus $7 D019363
- 650 _2
- $a cytochrom P-450 CYP1A2 $x genetika $x metabolismus $7 D019388
- 650 _2
- $a adukty DNA $x metabolismus $7 D018736
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a enzymy $x genetika $x metabolismus $7 D004798
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a metabolická inaktivace $7 D008658
- 650 _2
- $a nemoci ledvin $x chemicky indukované $7 D007674
- 650 _2
- $a myši $7 D051379
- 650 12
- $a myši knockoutované $7 D018345
- 650 _2
- $a NAD(P)H dehydrogenasa (chinon) $x antagonisté a inhibitory $7 D016660
- 650 _2
- $a NADPH-cytochrom c-reduktasa $x genetika $x metabolismus $7 D009251
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Frei, Eva
- 700 1_
- $a Arlt, Volker M. $7 xx0074763 $4
- 700 1_
- $a Schmeiser, Heinz H
- 773 0_
- $w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 44, č. 2 (2014), s. 135-45
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24152141 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20150401095532 $b ABA008
- 999 __
- $a ok $b bmc $g 1065809 $s 891336
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 44 $c 2 $d 135-45 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
- LZP __
- $a Pubmed-20150306